img

Global Nonalcoholic Steatohepatitis (NASH) Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Nonalcoholic Steatohepatitis (NASH) Market Insights, Forecast to 2034

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Market Analysis and InsightsGlobal Nonalcoholic Steatohepatitis (NASH) Market
Global Nonalcoholic Steatohepatitis (NASH) market is expected to reach to US$ 4637.6 million in 2023, with a positive growth of %, compared with US$ 3064.2 million in 2022. Backed with the increasing demand from downstream industries, Nonalcoholic Steatohepatitis (NASH) industry is evaluated to reach US$ 46230 million in 2033. The CAGR will be 46.7% during 2023 to 2033.
Non-alcoholic drinks, also known as mocktails or alcohol-free beverages, are beverages that do not contain any alcohol. These drinks are a popular choice for those who do not consume alcohol, including designated drivers, people who are underage, or individuals who wish to avoid alcohol for personal or health reasons. There are a wide variety of non-alcoholic drinks available, ranging from soft drinks to fresh juices, herbal infusions, and specialty mocktails. Some examples of non-alcoholic drinks include1. Soft DrinksThis category includes popular carbonated beverages like cola, lemon-lime sodas, ginger ale, and root beer. These drinks are often sweet and fizzy, providing a refreshing and enjoyable beverage option. 2. Fruit JuicesFreshly squeezed or packaged fruit juices, such as orange, apple, grapefruit, pineapple, or cranberry juice, are a common choice. These juices offer a natural and flavorful alternative to alcoholic beverages. 3. SmoothiesMade from a blend of fruits, vegetables, yogurt, and other ingredients, smoothies provide a nutritious and wholesome non-alcoholic option. They can be customized with various flavors and ingredients to suit individual preferences. 4. Herbal Infusions and TeaHerbal teas and infusions, such as chamomile, peppermint, green tea, or hibiscus tea, are popular choices. These beverages are caffeine-free and often have relaxing or soothing properties. 5. MocktailsThese are non-alcoholic cocktails that mimic the flavors and presentation of traditional cocktails. They are typically made with a combination of juices, sodas, and garnishes, providing a fancy and enjoyable experience without the alcohol. 6. Sparkling WaterCarbonated water or mineral water with added flavors or fruit infusions is a refreshing and hydrating option. It is often consumed plain or mixed with juices or syrups. These non-alcoholic drinks offer a variety of flavors, textures, and options for those who prefer not to consume alcohol. They are a great way to enjoy a beverage while socializing or relaxing without the effects of alcohol.
Report Covers
This report presents an overview of global Nonalcoholic Steatohepatitis (NASH) market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Nonalcoholic Steatohepatitis (NASH) market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Segment by Type
Obeticholic acid(OCA)
Selonsertib

Segment by Application


Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Nonalcoholic Steatohepatitis (NASH) introduction, etc. Nonalcoholic Steatohepatitis (NASH) Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Nonalcoholic Steatohepatitis (NASH)
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Obeticholic acid(OCA)
1.2.3 Selonsertib
1.3 Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2018-2033)
2.2 Global Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2018-2023)
2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2024-2033)
2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Nonalcoholic Steatohepatitis (NASH) by Players
3.1.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2018-2023)
3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2018-2023)
3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Nonalcoholic Steatohepatitis (NASH), Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
3.5 Global Key Players of Nonalcoholic Steatohepatitis (NASH) Head office and Area Served
3.6 Global Key Players of Nonalcoholic Steatohepatitis (NASH), Product and Application
3.7 Global Key Players of Nonalcoholic Steatohepatitis (NASH), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type
4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2018-2023)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2024-2033)
5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application
5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2018-2023)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
6.2.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023)
6.2.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033)
6.2.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023)
6.3.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033)
6.3.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
6.4.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
6.4.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
7.2.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023)
7.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033)
7.2.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application
7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023)
7.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033)
7.3.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
7.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
7.4.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
8.2 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type
8.2.1 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023)
8.2.2 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033)
8.2.3 China Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
8.3 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application
8.3.1 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023)
8.3.2 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033)
8.3.3 China Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
9.2 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type
9.2.1 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023)
9.2.2 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033)
9.2.3 Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
9.3 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application
9.3.1 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023)
9.3.2 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033)
9.3.3 Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
9.4 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region
9.4.1 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023)
9.4.3 Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
10.2.1 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
10.3.1 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
10.4.1 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.1.5 AstraZeneca Recent Developments
11.2 Arena Pharmaceuticals
11.2.1 Arena Pharmaceuticals Company Details
11.2.2 Arena Pharmaceuticals Business Overview
11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.2.5 Arena Pharmaceuticals Recent Developments
11.3 GSK
11.3.1 GSK Company Details
11.3.2 GSK Business Overview
11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.3.5 GSK Recent Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Details
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.4.5 Novo Nordisk Recent Developments
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.5.5 Roche Recent Developments
11.6 Vivus
11.6.1 Vivus Company Details
11.6.2 Vivus Business Overview
11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.6.5 Vivus Recent Developments
11.7 Arisaph Pharmaceuticals
11.7.1 Arisaph Pharmaceuticals Company Details
11.7.2 Arisaph Pharmaceuticals Business Overview
11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.7.5 Arisaph Pharmaceuticals Recent Developments
11.8 Cempra Pharmaceuticals
11.8.1 Cempra Pharmaceuticals Company Details
11.8.2 Cempra Pharmaceuticals Business Overview
11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.8.5 Cempra Pharmaceuticals Recent Developments
11.9 Galectin Therapeutics
11.9.1 Galectin Therapeutics Company Details
11.9.2 Galectin Therapeutics Business Overview
11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.9.5 Galectin Therapeutics Recent Developments
11.10 Galmed Pharmaceuticals
11.10.1 Galmed Pharmaceuticals Company Details
11.10.2 Galmed Pharmaceuticals Business Overview
11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.10.5 Galmed Pharmaceuticals Recent Developments
11.11 Genfit
11.11.1 Genfit Company Details
11.11.2 Genfit Business Overview
11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.11.5 Genfit Recent Developments
11.12 Gilead
11.12.1 Gilead Company Details
11.12.2 Gilead Business Overview
11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
11.12.5 Gilead Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Obeticholic acid(OCA)
Table 3. Key Players of Selonsertib
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2018-2023)
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2024-2033)
Table 10. Nonalcoholic Steatohepatitis (NASH) Market Trends
Table 11. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Table 12. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 13. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Table 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players (2018-2023)
Table 16. Global Top Nonalcoholic Steatohepatitis (NASH) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2022)
Table 17. Global Nonalcoholic Steatohepatitis (NASH) Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Nonalcoholic Steatohepatitis (NASH), Headquarters and Area Served
Table 20. Global Key Players of Nonalcoholic Steatohepatitis (NASH), Product and Application
Table 21. Global Key Players of Nonalcoholic Steatohepatitis (NASH), Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2018-2023)
Table 25. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2024-2033)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Application (2018-2023)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Application (2024-2033)
Table 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Nonalcoholic Steatohepatitis (NASH) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Nonalcoholic Steatohepatitis (NASH) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Nonalcoholic Steatohepatitis (NASH) Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2024-2033) & (US$ Million)
Table 63. AstraZeneca Company Details
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product
Table 66. AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 67. AstraZeneca Recent Developments
Table 68. Arena Pharmaceuticals Company Details
Table 69. Arena Pharmaceuticals Business Overview
Table 70. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 71. Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 72. Arena Pharmaceuticals Recent Developments
Table 73. GSK Company Details
Table 74. GSK Business Overview
Table 75. GSK Nonalcoholic Steatohepatitis (NASH) Product
Table 76. GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 77. GSK Recent Developments
Table 78. Novo Nordisk Company Details
Table 79. Novo Nordisk Business Overview
Table 80. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product
Table 81. Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 82. Novo Nordisk Recent Developments
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Nonalcoholic Steatohepatitis (NASH) Product
Table 86. Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 87. Roche Recent Developments
Table 88. Vivus Company Details
Table 89. Vivus Business Overview
Table 90. Vivus Nonalcoholic Steatohepatitis (NASH) Product
Table 91. Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 92. Vivus Recent Developments
Table 93. Arisaph Pharmaceuticals Company Details
Table 94. Arisaph Pharmaceuticals Business Overview
Table 95. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 96. Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 97. Arisaph Pharmaceuticals Recent Developments
Table 98. Cempra Pharmaceuticals Company Details
Table 99. Cempra Pharmaceuticals Business Overview
Table 100. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 101. Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 102. Cempra Pharmaceuticals Recent Developments
Table 103. Galectin Therapeutics Company Details
Table 104. Galectin Therapeutics Business Overview
Table 105. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
Table 106. Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 107. Galectin Therapeutics Recent Developments
Table 108. Galmed Pharmaceuticals Company Details
Table 109. Galmed Pharmaceuticals Business Overview
Table 110. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
Table 111. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 112. Galmed Pharmaceuticals Recent Developments
Table 113. Genfit Company Details
Table 114. Genfit Business Overview
Table 115. Genfit Nonalcoholic Steatohepatitis (NASH) Product
Table 116. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 117. Genfit Recent Developments
Table 118. Gilead Company Details
Table 119. Gilead Business Overview
Table 120. Gilead Nonalcoholic Steatohepatitis (NASH) Product
Table 121. Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023) & (US$ Million)
Table 122. Gilead Recent Developments
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2022 VS 2033
Figure 3. Obeticholic acid(OCA) Features
Figure 4. Selonsertib Features
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2022 VS 2033
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Online Provider Case Studies
Figure 9. Retail Pharmacy Case Studies
Figure 10. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region: 2022 VS 2033
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2022
Figure 15. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2022
Figure 17. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
Figure 19. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
Figure 20. North America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 21. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2018-2033) & (US$ Million)
Figure 24. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
Figure 25. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
Figure 26. Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 27. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2018-2033) & (US$ Million)
Figure 34. China Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
Figure 35. China Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
Figure 36. Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2018-2033) & (US$ Million)
Figure 37. Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
Figure 38. Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
Figure 39. Asia Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2018-2033)
Figure 40. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. China Taiwan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2018-2033)
Figure 48. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2018-2033)
Figure 49. Middle East, Africa, and Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Country (2018-2033)
Figure 50. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Israel Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. GCC Countries Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. AstraZeneca Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 57. Arena Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 58. GSK Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 59. Novo Nordisk Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 60. Roche Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 61. Vivus Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 62. Arisaph Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 63. Cempra Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 64. Galectin Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 65. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 66. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 67. Gilead Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed